跳至主要内容
临床试验/NCT01130584
NCT01130584已完成不适用

Pyruvate Kinase Isoform M2 (PKM2) as a Possible Biomarker for Cancer

National University Hospital, Singapore1 个研究点 分布在 1 个国家开始时间: 2010年4月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
试验地点
1

研究概览

简要总结

The purpose of this study is to determine if pyruvate kinase M2 (PKM2) can be used as a biomarker in cancer.

Pyruvate kinase M2 is more elevated in malignant pleural fluid than in plasma, and may be a useful biomarker to distinguish between malignant and non-malignant causes of pleural effusion. In addition, pyruvate kinase M2 has also been found to be elevated in saliva in cancer patients compared to controls. Measuring pyruvate kinase M2 in saliva may be used to diagnose cancer or monitor the treatment progress of cancer.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Any cancer patient with pleural effusion that is being drained through an indwelling chest-tube in an inpatient ward.

排除标准

  • Patient with a pleural effusion who does not have proven cancer or whose pleural effusion is not known to be malignant.

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验